Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study

1. Chari, A.
2. Rodriguez-Otero, P.
3. McCarthy, H.
4. Suzuki, K.
5. Hungria, V.
6. Sureda Balari, A.
7. Perrot, A.
8. Hulin, C.
9. Magen, H.
10. Iida, S.
11. Maisnar, V.
12. Karlin, L.
13. Pour, L.
14. Parasrampuria, D.A.
15. Masterson, T.
16. Kosh, M.
17. Yang, S.
18. Delioukina, M.
19. Qi, M.
20. Carson, R.
21. Touzeau, C.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1111/BJH.16980 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus